106 related articles for article (PubMed ID: 2552802)
1. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
2. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
4. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
5. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
6. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
7. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of fosfomycin on cisplatin-induced nephrotoxicity in patients with lung cancer.
Rojanasthien N; Kumsorn B; Atikachai B; Leotrakul S; Thongprasert S
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):121-5. PubMed ID: 11396752
[TBL] [Abstract][Full Text] [Related]
9. Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice.
Tokunaga J; Kobayashi M; Nakamura C; Kitagawa A; Arimori K; Nakano M
Ren Fail; 1997 May; 19(3):425-38. PubMed ID: 9154659
[TBL] [Abstract][Full Text] [Related]
10. [Renal tubular impairment after surgery].
Terashima S
Nihon Geka Gakkai Zasshi; 1989 Jul; 90(7):999-1008. PubMed ID: 2677665
[TBL] [Abstract][Full Text] [Related]
11. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels.
Hayashi M; Numaguchi M; Watabe H; Enomoto H; Yaoi Y
Acta Obstet Gynecol Scand; 1997 Jul; 76(6):590-5. PubMed ID: 9246969
[TBL] [Abstract][Full Text] [Related]
13. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin nephrotoxicity and protection by silibinin.
Gaedeke J; Fels LM; Bokemeyer C; Mengs U; Stolte H; Lentzen H
Nephrol Dial Transplant; 1996 Jan; 11(1):55-62. PubMed ID: 8649653
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
16. [Anticancer chemotherapy containing cisplatin in patients with lung cancer and kidney function].
Wiela-Hojeńska A; Passowicz-Muszyńska E; Orzechowska-Juzwenko K; Jankowska R; Hurkacz M; Unolt J; Weryńska B; Gołecki M; Dyła T
Pol Arch Med Wewn; 2002 Feb; 107(2):135-40. PubMed ID: 12107968
[TBL] [Abstract][Full Text] [Related]
17. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of cisplatin-induced nephrotoxicity in rats by tetramethylpyrazine, a major constituent of the Chinese herb Ligusticum wallichi.
Ali BH; Al-Moundhri M; Eldin MT; Nemmar A; Al-Siyabi S; Annamalai K
Exp Biol Med (Maywood); 2008 Jul; 233(7):891-6. PubMed ID: 18445776
[TBL] [Abstract][Full Text] [Related]
19. [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Ogura T; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):89-96. PubMed ID: 9464334
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]